Comparative Pharmacology
Head-to-head clinical analysis: ACTRON versus IBUPROFEN AND FAMOTIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTRON versus IBUPROFEN AND FAMOTIDINE.
ACTRON vs IBUPROFEN AND FAMOTIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
None Documented
None Documented
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (CrCl <30 mL/min).
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Category C
Category D/X
NSAID
NSAID